esreboxetine esreboxetine esreboxetine (developmental code names axs-14, pnu-165442g) is a selective norepinephrine reuptake inhibitor which was under development by pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. it is the (s,s)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison. esreboxetineclinical dataother namesaxs-14; pnu-165442groutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name (2s)-2-morpholine cas number98819-76-2 ypubchem cid65856iuphar/bps4808chemspider59268 nuniil8s50zy490keggd09340 ycomptox dashboard (epa)dtxsid601009938 chemical and physical dataformulac19h23no3molar mass313.397 g·mol−13d model (jsmol)interactive image smiles ccoc1=cc=cc=c1o(2cncco2)c3=cc=cc=c3 inchi inchi=1s/c19h23no3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20h,2,12-14h2,1h3/t18-,19-/m0/s1 nkey:cbqgyudmjhnjbx-oalutqoasa-n n ny (what is this?) (verify) however, recently it has been found that esreboxetine could be effective in fibromyalgia patients.